Optimizing the switching operation in monoclonal antibody production: Economic MPC and reinforcement learning

Abstract

'Benjamin Decardi‐Nelson' 'Jinfeng Liu'] Monoclonal antibodies (mAbs) have emerged as indispensable assets in medicine, and are currently at the forefront of biopharmaceutical product development [1]. However, the growing market demand and the substantial doses required for mAb clinical treatments necessitate significant progress in its large-scale production [2]. Most of the processes for industrial mAb production rely on batch operations, which result in significant downtime. The shift towards a fully continuous and integrated manufacturing process holds the potential to boost product yield and quality, while eliminating the extra expenses associated with storing intermediate products.